Literature DB >> 9414645

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.

F Zaja, A Rogato, D Russo, L Marin, F Silvestri, M Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9414645     DOI： 10.1111/j.1600-0609.1997.tb01694.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

Review 1.  Current and developing chemotherapy for CLL.

Authors:  Emili Montserrat
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.

Authors:  Michael D Jain; Christina A Bachmeier; Vania H Phuoc; Julio C Chavez
Journal:  Ther Clin Risk Manag       Date:  2018-05-31       Impact factor: 2.423

3.  Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).

Authors:  Janneke Hoogstad-van Evert; Ruud Bekkers; Nelleke Ottevanger; Nicolaas Schaap; Willemijn Hobo; Joop H Jansen; Leon Massuger; Harry Dolstra
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 4.  Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.

Authors:  Peter A Riedell; Michael R Bishop
Journal:  Ther Adv Hematol       Date:  2020-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.